Featured Research

from universities, journals, and other organizations

An Effective Target Of Biological Therapy For Hepatocellular Carcinoma

Date:
June 15, 2009
Source:
World Journal of Gastroenterology
Summary:
A research group in China applied a DNA vector-based STAT3-specific RNA interfering approach to block STAT3 signaling and to evaluate the biological consequences of STAT3 down-modulation on tumor growth using a tumor-bearing nude mice model. Silencing of STAT3 by RNAi suppresses tumor growth in vivo and STAT3 may act as an effective target for HCC therapy.

A research group in China applied a DNA vector-based STAT3-specific RNA interfering approach to block STAT3 signaling and to evaluate the biological consequences of STAT3 down-modulation on tumor growth using a tumor-bearing nude mice model. Silencing of STAT3 by RNAi suppresses tumor growth in vivo and STAT3 may act as an effective target for HCC therapy.

It has been shown that constitutively activated STAT3 is detected in many HCC cell lines and tissues. This suggests that STAT3 is a promising molecular target for HCC gene therapy. RNA interference (RNAi) is a post-transcriptional gene-silencing mechanism, in which the homologous RNA sequences could be introduced into cells that inhibit the expression of a particular gene through the introduction of short interfering RNAs (siRNA). There were a large number of confirmed reports that RNAi targeting oncogene could successfully inhibit the growth of tumor cells in vitro and in vivo. Hence, RNAi has been turned into a potent technology for tumor therapy. Yet, there are no reports about targeting STAT3 by RNAi in HCC.

A research article to be published on June 7, 2009 in the World Journal of Gastroenterology addresses this question. The research team led by Professor Piao from Liaoning Medical University and Jinlin University applied a DNA vector-based STAT3-specific RNA interfering approach to block STAT3 signaling and to evaluate the biological consequences of STAT3 down-modulation on tumor growth using a tumor-bearing nude mice model.

The research revealed that silencing STAT3 by RNAi inhibited the growth of HCC cells in vivo, induced apoptosis, and had significant antineoplastic efficacy. RNAi that targets STAT3 has a clear therapeutic effect in HCC. Therefore, STAT3 may become an important target of biological therapy in HCC, which brings hope of clinical therapy using RNAi oligonucleotide drugs. It may also offer a theoretical and experimental foundation for the clinical application of synthetic dsRNA-based RNAi.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Li J, Piao YF, Jiang Z, Chen L, Sun HB. Silencing of signal transducer and activator of transcription 3 expression by RNA interference suppresses growth of human hepatocellular carcinoma in tumor-bearing nude mice. World Journal of Gastroenterology, 2009; 15 (21): 2602 DOI: 10.3748/wjg.15.2602

Cite This Page:

World Journal of Gastroenterology. "An Effective Target Of Biological Therapy For Hepatocellular Carcinoma." ScienceDaily. ScienceDaily, 15 June 2009. <www.sciencedaily.com/releases/2009/06/090615094044.htm>.
World Journal of Gastroenterology. (2009, June 15). An Effective Target Of Biological Therapy For Hepatocellular Carcinoma. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/06/090615094044.htm
World Journal of Gastroenterology. "An Effective Target Of Biological Therapy For Hepatocellular Carcinoma." ScienceDaily. www.sciencedaily.com/releases/2009/06/090615094044.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins